AMG 337, a selective small-molecule MET inhibitor, was evaluated in Asian patients with advanced solid tumors. Eligible patients orally self-administered AMG 337; the initial dose of 150 mg once daily (QD) was escalated to 300 mg QD (modified 3+3+3 design). Treatment continued until disease progression, intolerability, or death. The primary endpoint was adverse events (AEs) and clinical abnormalities defined as dose-limiting toxicities (DLTs). Secondary endpoints included other AEs, pharmacokinetics and tumor response. Eleven patients were enrolled. No DLTs occurred. The most common treatment-emergent AEs were headache (73%) and nausea (45%). C max and AUC 0-24 exposures increased proportionally with dose; t 1/2 was comparable between groups; plasma accumulation was minimal over 28 days. One patient (150 mg) had partial response; one patient (300 mg) had stable disease. Safety, tolerability, pharmacokinetics and efficacy of AMG 337 in Asian patients were consistent with those observed in Western patient populations. The study was terminated early.
Introduction
Binding of the tyrosine kinase receptor MET to its ligand, hepatocyte growth factor (HGF), causes MET receptor dimerization and activates signaling cascades that mediate tumor proliferation, migration, metastasis, and angiogenesis and tumor cell survival (1) (2) (3) (4) (5) . MET gene amplification and overexpression have been observed in many solid tumors, including gastric, esophageal, and colorectal cancers and glioblastoma (4, (6) (7) (8) (9) (10) and have been shown to correlate with poor prognosis (2) (3) (4) . Given the role of the MET/HGF pathway in tumor development and progression, there is interest in targeting this pathway in patients with cancer (11, 12) . Although several investigational small-molecule tyrosine kinase inhibitors and antibodies that target MET or HGF have shown antitumor activity in subgroups of patients with MET-expressing or MET-amplified solid tumors (4, 13, 14) , improved outcomes have not been observed in larger clinical trials (15) (16) (17) .
AMG 337 is a highly selective small-molecule MET inhibitor that blocks MET kinase activity (18, 19) . AMG 337 selectively inhibits the proliferation of MET-amplified tumor cell lines, inhibits HGFinduced MET phosphorylation and Gab-1 phosphorylation in METdependent tumor models, and reduces tumor xenograft growth in MET-amplified gastric cancer models (18, 19) . In the first-in-human Phase 1 clinical study, AMG 337 had manageable toxicity with antitumor activity in adults with advanced solid tumors (20, 21) .
Given the role of the MET/HGF pathway in gastric cancer (4, 6, 9) , the high mortality of patients with gastric cancer (22) , and the higher incidence of gastric cancer in Asian populations than Western populations (23) , use of MET inhibitors may represent an important treatment option for this patient population. This study was designed to evaluate potential differences in AMG 337 toxicity and antitumor responses in Asian patients with advanced solid tumors compared with Western patient populations who received AMG 337 in the first-in-human clinical trial (20, 21) . The objectives of this study were to determine the tolerability (defined as doselimiting toxicities [DLTs]) of AMG 337 up to 300 mg once daily (QD) in Asian patients and evaluate the safety, pharmacokinetics and efficacy of AMG 337.
Patients and methods

Patients
Patients were eligible if they were ≥20 years of age, had pathologically confirmed advanced solid tumors for which they had received prior therapy, had refused standard therapy, or for which no standard therapy was available; had adequate organ function; and an Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Patients were excluded if they had central nervous system metastasis, were candidates for curative surgery or definitive chemoradiation, had a history of arterial thrombosis or vascular ischemic events, had peripheral edema grade >1, had previously received small-molecule MET inhibitors, had received strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 14 days, had therapeutic or palliative radiation treatment within 14 days, or were experiencing toxicities from radiation therapy. Patients were required to self-administer AMG 337 orally as a whole capsule. The protocol was approved by each center's independent ethics committee; patients provided written informed consent. This study was conducted at two centers in Japan (National Cancer Center Hospital East, Kashiwa, Chiba, Japan, and Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, Japan).
Study design and treatment
This was an open-label, Phase 1 study evaluating the tolerability, safety, pharmacokinetics, and efficacy of AMG 337 in Asian patients. Dose escalation was based on a modified 3+3+3 study design ( Supplementary Fig. S1 ). The first cohort of three patients received AMG 337 150 mg QD orally (Cohort A). A second cohort was to be given AMG 337 300 mg QD (Cohort B) if either no DLTs occurred in the first three patients in the 150-mg cohort; 1 DLT occurred in the first six patients; or ≤2 DLTs occurred in the first nine patients. The MTD was determined to have been exceeded if ≥3 subjects in a cohort experienced a DLT. The primary endpoint of the study was adverse events (AEs) and clinical abnormalities defined as DLTs. DLTs were defined as grade ≥3 non-hematologic or Grade 4 hematologic AEs considered possibly related to AMG 337 that occurred during the first 28 days of treatment, with certain qualifications (Supplementary Material). Key secondary endpoints included other AEs, pharmacokinetic parameters, and tumor response.
This was designed as a Phase 1/2 study; however, interim analysis of a separate Phase 2 study of AMG 337 in patients with MET-amplified gastric, gastroesophageal junction or esophageal adenocarcinoma or other MET-amplified solid tumors (24) , indicated lower efficacy than was expected based on Phase 1 results (20, 21) . Therefore, the current study was terminated early and its Phase 2 portion was canceled. Because of the early termination, some analyses were not performed and the sample size was smaller than planned. The Phase 1 portion was initially designed to potentially allow additional dose cohorts (200 mg QD and 150 mg or 200 mg twice daily); these cohorts were not enrolled. A dose deescalation 200-mg QD cohort (Cohort C) was to be initiated only if ≥3 of nine patients in the 300-mg QD cohort experienced DLTs, which did not occur. Dose cohorts of AMG 337 150 mg (Cohort D) and 200 mg twice daily (Cohort E) would have been allowed after the Phase 2 dose was identified and concurrent with the Phase 2 portion of the study, but these cohorts did not enroll because the Phase 2 portion of the study was canceled.
Assessments
AEs were graded and classified according to the Common Terminology Criteria for Adverse Events, version 4.0. Blood sampling was performed predose on weeks 1, 3, 5, 9, 17, 25, and 33 and 3 h postdose on weeks 1, 9, and 17 for pharmacokinetic assessment of AMG 337. Tumors were assessed using computed tomography or magnetic resonance imaging of the chest, abdomen or pelvis, with scans performed at screening, every 8 weeks until week 32, and every 12 weeks, thereafter. Tumor assessments were performed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (25) by investigators.
Statistical analyses
The safety, DLT, pharmacokinetics and efficacy analysis sets included patients given ≥1 dose of AMG 337; the DLT set included patients who were either monitored for 28 days of therapy or experienced a DLT within 28 days; the pharmacokinetics set included patients who underwent blood sampling and had measurable concentrations above the assay's limit of quantification. Objective response rate was evaluated in patients with measurable tumors per RECIST at baseline.
Non-compartmental pharmacokinetics analyses were performed using Phoenix WinNonlin v.6.4 software (Pharsight, St. Louis, MO). Estimates of maximum concentration (C max ), time to C max (t max ), area under the plasma concentration-time curve from 0 to 24 h (AUC 0-24 ), and terminal half-life (t 1/2 ) were determined after oral administration of 150 mg or 300 mg AMG 337 QD.
Results
Patient characteristics
The study period was 15 April 2014 to 5 November 2015 (data cutoff). Twenty-four patients were screened; 11 were enrolled and received AMG 337 (150 mg, n = 4; 300 mg, n = 7). Two patients did not complete the 28-day DLT window: one patient in the 150-mg cohort withdrew consent on Day 1, and another patient in the 300-mg cohort experienced an AE on Day 8. In keeping with protocol, additional patients were enrolled. The median (range) age of the patients was 64 (41-74) years. Six patients (55%) had received >2 lines of therapy, all patients had an ECOG status of 0 or 1, and all had metastatic disease at baseline. The most common tumor types were gastric and liver cancer (n = 2, each; Supplementary Table S1). Most patients (n = 10) discontinued AMG 337 treatment (disease progression, n = 6; AEs, n = 3; patient request, n = 1). At data cutoff, one patient remained on study. Median follow-up time was 11.5 months.
Dose-limiting toxicities and adverse events
No DLTs occurred. Three patients had treatment-emergent AEs of grade ≥3: one patient in the 150-mg cohort (Grade 3 hyponatremia) and two patients in the 300-mg cohort (one patient with Grade 3 dyspnea, and one patient with Grade 4 abnormal hepatic function and Grade 3 lymphopenia). There were no fatal AEs (Table 1) . Two patients in the 300-mg cohort had serious AEs (Grade 4 abnormal hepatic function, Grade 3 dyspnea; n = 1, each). Three patients in the 300-mg cohort had AEs that led to AMG 337 discontinuation (Grade 2 headache, Grade 4 abnormal hepatic function, and liver injury, n = 1, each). AEs of interest included grade ≥2 headache (150-mg cohort, n = 2 [50%]; 300-mg cohort; n = 5 [71%]), grade ≥2 drug-related hepatic disorder (150-mg cohort, n = 2 [50%]; 300-mg cohort, n = 2 [29%]), and low-grade edema (150-mg cohort, n = 2 [50%]; 300-mg cohort, n = 2 [29%]). Additional AEs of interest are shown in Table 1 .
Pharmacokinetics
Pharmacokinetic parameters were estimated after single and repeated oral administration of 150 mg or 300 mg AMG 337 QD on Days 1 and 28 (Table 2) . AMG 337 accumulation was minimal over 28 days; mean estimates of C max and AUC 0-24 increased approximately proportionally with dose over the 2-fold range of AMG 337 doses tested. A mean t 1/2 estimate of 6.51 h after single 300-mg dosing was similar to the observed t 1/2 after single 150-mg dosing in one patient with available data. Mean (SD) plasma concentration-time profiles after oral dosing at 150 mg and 300 mg AMG 337 QD on Days 1 and 28 are shown in Supplementary Fig. S2A and S2B, respectively.
Efficacy
Of 11 patients, 8 had measurable disease (150 mg, n = 3; 300 mg, n = 5). One patient with liver cancer (150-mg cohort) had a partial response (time to response, 5.6 months; duration of response, 12.9 months [censored]). This patient remained on AMG 337 at data cutoff. One patient with liver cancer (300-mg cohort) had stable disease (censored). The remaining six patients had progressive disease.
Discussion
Results of this Phase 1 study were similar to those previously reported for AMG 337 (20, 21) . Headache was the most frequently reported AE in this study, consistent with the AE profile of AMG 337 previously observed (20, 21) . Among Asian patients, AMG 337 exposures increased with dose; accumulation was minimal after 28 days, similar to previous observations. The estimated t 1/2 of 6.5 h was comparable to the 4.6-7.4 h range previously reported (20) . Among eight patients with measurable disease, one woman with liver cancer in the AMG 337 300-mg QD cohort had a partial response lasting 12.9 months and remained on study as of data cutoff.
Headache was observed in 50% of patients who received AMG 337 150-mg QD and 86% of patients who received AMG 337 300-mg QD. This finding was comparable to previous studies that reported a dose-dependent increase in headaches in patients who received AMG 337 (20, 21) , which was possibly due to the inhibition of adenosine transporters (26, 27) . Consistent with findings with other inhibitors of the MET pathway (28), low-grade peripheral edema occurred in 27% of patients who received AMG 337; no grade ≥3 peripheral edema was observed in this study. Although early studies reported that some patients with cancers driven by MET amplification or MET overexpression responded well to MET inhibitors (4, 13, 14, 29) , findings from several Phase 3 studies of MET inhibitors have been disappointing (15) (16) (17) . The reason for the failure of MET inhibitors to significantly prolong overall survival in populations selected for MET amplification or overexpression is not yet clear. Strategies that refine patient selection criteria to identify patients most likely to respond to MET inhibitors may be necessary. Alternatively, inhibition of the MET pathway alone may be insufficient to improve outcomes for many patients. The MET pathway has been shown to play a role in the resistance of patients to other targeted therapies (e.g. epidermal growth factor receptor inhibitors) (30, 31) ; it is possible that investigation of MET inhibitors in combination with these targeted therapies may be appropriate.
In conclusion, the toxicity and pharmacokinetics of AMG 337 in Asian/Japanese patients were similar to those observed in Western patient populations (20, 21) . One patient had a partial response over one year in this small study. Further research should focus on identifying patients who may benefit from AMG 337 treatment.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical Oncology online.
